• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

LMWH during Pregnancy: Planned Induction vs Spontaneous Delivery and Eligibility of Epidural

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • It is unclear which of the following options for pregnant women using low weight molecular heparin (LMWH) is associated with better perinatal outcomes, including the best chance of having neuraxial analgesia
    • Scheduled delivery 12 hours following termination of anticoagulant treatment vs
    • Spontaneous onset of delivery
  • Neuraxial anesthesia is generally available to patients if the time from last prophylactic LMWH dose ≤10 to 12 hours
  • Rottenstreich et al. (BJOG, 2020) examined the outcomes of planned induction of labor vs spontaneous onset of labor among women using LMWH

METHODS:

  • Retrospective cohort study
  • Participants
    • Use of prophylactic LMWH therapy during pregnancy
    • Vaginal delivery from 2018 to 2019
  • Exposures
    • Planned induction of labor
    • Spontaneous onset of labor
  • Primary outcome
    • Duration of anticoagulation interruption
    • Eligibility to receive neuraxial anesthesia

RESULTS:

  • 199 women | >90% considered at risk for postpartum VTE and were given postpartum thromboprophylaxis
    • Spontaneous onset of labor: 39.2%
    • Planned induction: 60.8%
  • Women who presented with spontaneous onset of labor had a shorter
    • Median admission-to-delivery interval (P < 0.001)
      • Spontaneous: 4.7 hours
      • Planned: 29.3 hours
    • Last LMWH injection to delivery interval (P <0.001)
      • Spontaneous: 25.8 hours
      • Planned: 48.2 hours
    • LMWH injection to the first postpartum LMWH injection interval (P <0.001)
      • Spontaneous: 41.2 hours
      • Planned: 63.7 hours
  • Eligibility for neuraxial analgesia was higher among the planned group (P <0.001)
    • Spontaneous: 88.5%
    • Planned: 100%
  • Rates of the following were similar between the groups
    • Postpartum hemorrhage
    • Blood transfusion
  • Thrombotic events were documented among women in the planned group but there was no statistical difference between groups (P=0.16)
    • Spontaneous: no events
    • Planned: 3.3% (4 women)

CONCLUSION:

  • The planned induction group experienced postpartum thrombotic events (though not statistically significant)
    • The authors hypothesize that this may be due to the prolonged duration of anticoagulation interruption
  • There were comparable rates of bleeding complications between the groups
  • Most women (almost 90%) in the spontaneous onset of labor group were eligible to receive neuraxial anesthesia because time from last LMWH injection until active labor was >12 hours
  • The authors state that while prospective studies are needed

The risk of not being eligible for neuraxial anaesthesia following spontaneous onset of labour was relatively low

Thus, we do not support the routine offering of induction of labour solely due to the use of prophylactic anticoagulation therapy

A multidisciplinary, individualised approach should be implemented

Learn More – Primary Sources:

Planned induction versus spontaneous delivery among women using prophylactic anticoagulation therapy: a retrospective study

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

What is the Risk for Recurrent VTE after Stopping Anticoagulation Treatment?
When to Stop Anticoagulation Following a DVT or Pulmonary Embolus?
What is the Risk for Venous Thromboembolism Following Cesarean Section?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site